Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Parkinson's disease.

ABSTRACT: Despite an ever-growing prevalence and increasing economic burden of Alzheimer's disease (AD) and Parkinson's disease (PD), recent advances in drug development have only resulted in minimally effective treatment. In AD, along with amyloid and tau phosphorylation, there is an associated increase in inflammation/glial activation, a decrease in synaptic function, an increase in astrocyte activation, and a state of insulin resistance. In PD, along with α-synuclein accumulation, there is associated inflammation, synaptic dysfunction, dopaminergic neuronal loss, and some data to suggest insulin resistance. Therapeutic strategies for neurodegenerative disorders have commonly targeted individual pathological processes. An effective treatment might require either utilization of multiple drugs which

SUBMITTER: Nowell J 

PROVIDER: S-EPMC9812772 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature